Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy.
Hyun-Chang Ko, Yu Ri Woo, Joo Yeon Ko, Hye One Kim, Chan Ho Na, Youin Bae, Young-Joon Seo, Min Kyung Shin, Jiyoung Ahn, Bark-Lynn Lew, Dong Hun Lee, Sang Eun Lee, Sul Hee Lee, Yang Won Lee, Ji Hyun Lee, Yong Hyun Jang, Jiehyun Jeon, Sun Young Choi, Ju Hee Han, Tae Young Han, Sang Wook Son, Sang Hyun Cho
{"title":"Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy.","authors":"Hyun-Chang Ko, Yu Ri Woo, Joo Yeon Ko, Hye One Kim, Chan Ho Na, Youin Bae, Young-Joon Seo, Min Kyung Shin, Jiyoung Ahn, Bark-Lynn Lew, Dong Hun Lee, Sang Eun Lee, Sul Hee Lee, Yang Won Lee, Ji Hyun Lee, Yong Hyun Jang, Jiehyun Jeon, Sun Young Choi, Ju Hee Han, Tae Young Han, Sang Wook Son, Sang Hyun Cho","doi":"10.5021/ad.24.153","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed.</p><p><strong>Objective: </strong>This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based practices.</p><p><strong>Methods: </strong>The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved.</p><p><strong>Results: </strong>The guidelines provide detailed recommendations on foundational therapies, including the use of moisturizers, cleansing and bathing practices, allergen avoidance, and patient education. Guidance on topical therapies, such as topical corticosteroids and calcineurin inhibitors, is also provided to help manage inflammation and maintain skin barrier function in patients with AD. Additionally, recommendations on conventional systemic therapies, including corticosteroids, cyclosporine, and methotrexate, are provided for managing moderate to severe AD.</p><p><strong>Conclusion: </strong>KADA's updated AD guidelines offer clinicians evidence-based strategies focused on basic therapies, topical therapies, and conventional systemic therapies, equipping them to enhance quality of care and improve patient outcomes in AD management.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 4","pages":"201-215"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318780/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5021/ad.24.153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed.
Objective: This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based practices.
Methods: The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved.
Results: The guidelines provide detailed recommendations on foundational therapies, including the use of moisturizers, cleansing and bathing practices, allergen avoidance, and patient education. Guidance on topical therapies, such as topical corticosteroids and calcineurin inhibitors, is also provided to help manage inflammation and maintain skin barrier function in patients with AD. Additionally, recommendations on conventional systemic therapies, including corticosteroids, cyclosporine, and methotrexate, are provided for managing moderate to severe AD.
Conclusion: KADA's updated AD guidelines offer clinicians evidence-based strategies focused on basic therapies, topical therapies, and conventional systemic therapies, equipping them to enhance quality of care and improve patient outcomes in AD management.